74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Novocure Ltd
Closed
SectorHealthcare
18.53 4.75
Overview
Share price change
24h
Min
17.31
Max
19.07
Income | -35M -66M |
|---|---|
Sales | 6.2M 161M |
EPS | -0.61 |
Profit margin | -40.878 |
Employees | 1,488 |
EBITDA | 19M -11M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +83.29% upside |
Next Earnings | 24 Jul 2025 |
|---|
Market Cap | -561M 1.7B |
|---|---|
Previous open | 13.78 |
Previous close | 18.53 |
Technical Score
By Trading Central
Confidence
Very Strong Bullish Evidence
Novocure Ltd Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Novocure Ltd Forecast
Price Target
By TipRanks
83.29% upside
12 Months Forecast
Average 34 USD 83.29%
High 40 USD
Low 27 USD
Based on 7 Wall Street analysts offering 12 month price targets forNovocure Ltd - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
